Live Breaking News & Updates on சாலிக்ஸ் மருந்துகள் லிமிடெட்
Stay updated with breaking news from சாலிக்ஸ் மருந்துகள் லிமிடெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article ResearchAndMarkets.com s offering. According to this report the market is expected to reach US$ 6,025.11 million by 2027 from US$ 4,338.61 million in 2019; it is estimated to grow at a CAGR of 4.3% from 2020 to 2027. The report highlights trends prevailing in the market, and the factors driving and hindering the market growth. The market growth is primarily attributed to the increasing diabetes prevalence and growing geriatric population. However, side-effects of gastroparesis drugs restrain the growth of the market. On the basis of type, the gastroparesis market is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic type held the largest share of the market in 2019; however, the market for the diabetic type is estimated to grow at the highest CAGR during the forecast period. The rising number of research and development activities pertaining to the management of diabetic gastroparesis is estimated t ....
Share this article Share this article ResearchAndMarkets.com s offering. The global irritable bowel syndrome with diarrhea market is rising at a significant pace, projected to rise at a CAGR of 11.3% during the estimated period from 2020 to 2028, starting from US$ 423.3 Mn in 2019. Recent approvals for two new prescription drugs to treat irritable bowel syndrome with diarrhea (IBS-D) have become the biggest phenomenon in the IBS-D drugs market. These approvals are viewed as a breakthrough step in the long struggle to discover an effective treatment for IBS-D. Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora. Xifaxan had been used off-label for treating IBS-D, thus direct approval for treating IBS-D will lead to growth in demand for Xifaxan during the forecast period. Drugs such as loperamide will experience a slack in demand due ....
Share this article Share this article ResearchAndMarkets.com s offering. The global opioid induced constipation drugs market is rising at a significant pace, projected to rise at a CAGR of 4.7% during the estimated period from 2020 to 2028, starting from US$ 2,656.4 Mn in 2019. The mechanism of action of opioid analgesics through binding to the mu, delta, and kappa receptors present in the brain by crossing the blood-brain barrier and giving the desired analgesic effect to treat non-cancer pain. In addition, the opioids bind to the mu receptors present in the gastrointestinal tract, which result in a contraction of the smooth muscles and alter the peristaltic movement causing constipation. Usually, the patients opt for over the counter osmotic laxatives and stimulant cathartics, which have been beneficial in providing relief from constipation in patients taking opioid analgesics for 3-4 weeks. In patients seeking palliative care, doctors prescribe mu-receptor anta ....
Press release content from Wired Release. The AP news staff was not involved in its creation. Chronic Idiopathic Constipation (Cic) Drugs Market by Manufacturers,Revenue,Trend and Forecast Report 2021-2026- Market.biz January 29, 2021 GMT Pune, Maharashtra, India, January 29 2021 (Wiredrelease) MarketDesk :The Global Chronic Idiopathic Constipation (Cic) Drugs Market 2021 covers explicit data related to the development rate, market estimates, drivers, limitations, future based demand, and revenue during the forecast period 2021-2026. The Global Chronic Idiopathic Constipation (Cic) Drugs Market contained accumulated data from various primary and secondary sources. This information has been verified and validated by the market analysts, thus providing significant insights to the researchers, experts, managers, and other industry professionals. This document further helps in understanding market development, applications, specifications, and market challenges. ....